The Co-Expression of Melanoma-Antigen Family a Proteins and New York Esophageal Squamous Cell Carcinoma-1 in Breast Cancer: A Pilot Study

References

• Anastasiadi Z, Lianos GD, Ignatiadou E, Harissis HV, Mitsis M. Breast cancer in young women: an overview. Updates Surg. 2017;69(3):313–317. doi:10.1007/s13304-017-0424-128260181
   PubMed Web of Science ®Google Scholar
• Greaney ML, Sprunck-Harrild K, Ruddy KJ, et al. Study protocol for young & strong: a cluster randomized design to increase attention to unique issues faced by young women with newly diagnosed breast cancer. BMC Public Health. 2015;15(1):37. doi:10.1186/s12889-015-1346-925636332
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang Y, Zhang L. Expression of cancer-testis antigens in esophageal cancer and their progress in immunotherapy. J Cancer Res Clin Oncol. 2019;145(2):281–291. doi:10.1007/s00432-019-02840-330656409
   PubMed Web of Science ®Google Scholar
• Raghavendra A, Kalita-de Croft P, Vargas AC, et al. Expression of MAGE-A and NY-ESO-1 cancer/testis antigens is enriched in triple-negative invasive breast cancers. Histopathology. 2018;73(1):68–80. doi:10.1111/his.1349829465777
   PubMed Web of Science ®Google Scholar
• Kerkar SP, Wang Z-F, Lasota J, et al. MAGE-A is more highly expressed than NY-ESO-1 in a systematic immunohistochemical analysis of 3668 cases. J Immunother. 2016;39(4):181–187. doi:10.1097/CJI.000000000000011927070449
   PubMed Web of Science ®Google Scholar
• Schooten E, Di Maggio A, van Bergen En Henegouwen PMP, Kijanka MM. MAGE-A antigens as targets for cancer immunotherapy. Cancer Treat Rev. 2018;67:54–62. doi:10.1016/j.ctrv.2018.04.00929763778
   PubMed Web of Science ®Google Scholar
• Raza A, Merhi M, Inchakalody VP, et al. Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy. J Transl Med. 2020;18(1):140. doi:10.1186/s12967-020-02306-y32220256
   PubMed Web of Science ®Google Scholar
• Jäger E, Stockert E, Zidianakis Z, et al. Humoral immune responses of cancer patients against “Cancer-Testis” antigen NY-ESO-1: correlation with clinical events. Int J Cancer. 1999;84(5):506–510. doi:10.1002/(sici)1097-0215(19991022)84:5<506::aid-ijc10>3.0.co;2-610502728
   PubMed Web of Science ®Google Scholar
• van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254(5038):1643–1647. doi:10.1126/science.18407031840703
   PubMed Web of Science ®Google Scholar
• Matković B, Juretić A, Spagnoli GC, et al. Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: retrospective immunohistochemical study. Croat Med J. 2011;52(2):171–177. doi:10.3325/cmj.2011.52.17121495200
   PubMed Web of Science ®Google Scholar
• Roguljic A, Spagnoli G, Juretic A, Sarcevic B, Banovic M, Beketic Oreskovic L. Possible predictive role of cancer/testis antigens in breast ductal carcinoma in situ. Oncol Lett. 2018;16(6):7245–7255. doi:10.3892/ol.2018.954430546463
   PubMed Web of Science ®Google Scholar
• Pourmaleki M, Young JH, Socci ND, et al. Extramammary Paget disease shows differential expression of B7 family members B7-H3, B7-H4, PD-L1, PD-L2 and cancer/testis antigens NY-ESO-1 and MAGE-A. Oncotarget. 2019;10(58):6152–6167. doi:10.18632/oncotarget.2724731692889
   PubMedGoogle Scholar
• Bandić D, Juretić A, Sarcević B, et al. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study. Croat Med J. 2006;47(1):32–41.16489695
   PubMed Web of Science ®Google Scholar
• Badovinac ČT, Spagnoli G, Juretić A, Jakić-Razumović J, Podolski P, Šarić N. High expression of MAGE-A10 cancer-testis antigen in triple-negative breast cancer. Med Oncol. 2012;29(3):1586–1591. doi:10.1007/s12032-011-0120-922116775
   PubMed Web of Science ®Google Scholar
• Chen YT, Ross DS, Chiu R, et al. Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. PLoS One. 2011;6(3):e17876. doi:10.1371/journal.pone.001787621437249
   PubMed Web of Science ®Google Scholar
• Laban S, Atanackovic D, Luetkens T, et al. Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer. Int J Cancer. 2014;135(5):1142–1152. doi:10.1002/ijc.2875224482145
   PubMed Web of Science ®Google Scholar
• Tio D, Willemsen M, Krebbers G, et al. Differential expression of cancer testis antigens on lentigo maligna and lentigo maligna melanoma. Am J Dermatopathol. 2020;42(8):625–627. doi:10.1097/DAD.000000000000160732701706
   PubMed Web of Science ®Google Scholar
• Ahn S, Woo JW, Lee K, Park SY. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J Pathol Transl Med. 2020;54(1):34–44. doi:10.4132/jptm.2019.11.0331693827
   PubMed Web of Science ®Google Scholar
• Kanapathipillai M. Treating p53 mutant aggregation-associated cancer. Cancers. 2018;10(6):154. doi:10.3390/cancers10060154
   PubMed Web of Science ®Google Scholar
• Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol. 2007;8(4):275–283. doi:10.1038/nrm214717380161
   PubMed Web of Science ®Google Scholar
• Veit JA, Heine D, Thierauf J, et al. Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck. Head Neck. 2016;38(7):1008–1016. doi:10.1002/hed.2440326874246
   PubMed Web of Science ®Google Scholar
• Caballero OL, Shousha S, Zhao Q, Simpson AJG, Coombes RC, Neville AM. Expression of cancer/testis genes in ductal carcinoma in situ and benign lesions of the breast. Oncoscience. 2013;1(1):14–20. doi:10.18632/oncoscience.425593980
   PubMedGoogle Scholar
• Sendur MA, Aksoy S, Altundag K. Pertuzumab in HER2-positive breast cancer. Curr Med Res Opin. 2012;28(10):1709–1716. doi:10.1185/03007995.2012.72813222953713
   PubMed Web of Science ®Google Scholar